The city of Los Angeles, California, currently has 15 active clinical trials seeking participants for Ulcerative Colitis research studies.
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
Recruiting
Protocol Summary Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative colitis. Short Title: ExoFlo for ulcerative colitis Phase: 1 Methodology: Open label Study Duration: 24 months Subject Participation: 58 weeks Single or Multi-Site: Multi-Site
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/09/2024
Locations: Direct Biologics Investigational Site, Los Angeles, California
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
Recruiting
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/24/2023
Locations: Southern California Research Institute Medical Group, Inc., Los Angeles, California
Conditions: Ulcerative Colitis
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Los Angeles, California
Conditions: Ulcerative Colitis